<HashMap><database>biostudies-literature</database><scores><citationCount>0</citationCount><reanalysisCount>0</reanalysisCount><viewCount>75</viewCount><searchCount>0</searchCount></scores><additional><omics_type>Unknown</omics_type><volume>133(21)</volume><submitter>Shan X</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Recent studies have demonstrated that microRNAs (miRNAs) in the blood circulation can serve as promising diagnostic markers for cancers. This four-stage study aimed at finding serum miRNAs as potential biomarkers for lung adenocarcinoma (LA) diagnosis.&lt;h4>Methods&lt;/h4>The study was carried out between 2016 and 2017. The Exiqon miRNA qPCR panel (3 LA vs. 1 normal control [NC] pooled serum samples) was used for initial screening to acquire miRNA profiles. Thirty-five dysregulated miRNAs were further evaluated in the training (24 LA vs. 24 NCs) and testing stages (110 LA vs. 110 NCs) using quantitative real-time polymerase chain reaction assays.&lt;h4>Results&lt;/h4>Four serum miRNAs (miR-133a-3p, miR-584-5p, miR-10b-5p, and miR-221-3p) were significantly overexpressed in LA patients compared with NCs. The diagnostic value of the four-miRNA panel was validated by an external cohort (36 LA vs. 36 NCs). The areas under the receiver operating characteristic curve of the four-miRNA panel in the training, testing, and external validation stages were 0.734, 0.803, and 0.894 respectively. Meanwhile, the expression level of miR-221-3p was much higher in LA tumor samples than that in the adjacent normal tissues (19 LA vs. 19 NCs). The expression level of miR-10b-5p was also elevated in the serum-derived exosomes samples (18 LA vs. 18 NCs). The expression of miR-133a-3p, miR-584-5p, and miR-10b-5p was significantly elevated in LA patients with epidermal growth factor receptor mutation compared with NCs.&lt;h4>Conclusion&lt;/h4>The study established a four-miRNA signature in serum that could improve the diagnostic capability of LA.</pubmed_abstract><journal>Chinese medical journal</journal><pagination>2532-2542</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7722592</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Serum microRNA expression profiling revealing potential diagnostic biomarkers for lung adenocarcinoma.</pubmed_title><pmcid>PMC7722592</pmcid><pubmed_authors>Liu QX</pubmed_authors><pubmed_authors>Shan X</pubmed_authors><pubmed_authors>Zhang H</pubmed_authors><pubmed_authors>Liu P</pubmed_authors><pubmed_authors>Tang JW</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors><pubmed_authors>Zhu W</pubmed_authors><pubmed_authors>Zhou X</pubmed_authors><pubmed_authors>Wang TS</pubmed_authors><pubmed_authors>Zhu DX</pubmed_authors><pubmed_authors>Wen W</pubmed_authors><view_count>75</view_count></additional><is_claimable>false</is_claimable><name>Serum microRNA expression profiling revealing potential diagnostic biomarkers for lung adenocarcinoma.</name><description>&lt;h4>Background&lt;/h4>Recent studies have demonstrated that microRNAs (miRNAs) in the blood circulation can serve as promising diagnostic markers for cancers. This four-stage study aimed at finding serum miRNAs as potential biomarkers for lung adenocarcinoma (LA) diagnosis.&lt;h4>Methods&lt;/h4>The study was carried out between 2016 and 2017. The Exiqon miRNA qPCR panel (3 LA vs. 1 normal control [NC] pooled serum samples) was used for initial screening to acquire miRNA profiles. Thirty-five dysregulated miRNAs were further evaluated in the training (24 LA vs. 24 NCs) and testing stages (110 LA vs. 110 NCs) using quantitative real-time polymerase chain reaction assays.&lt;h4>Results&lt;/h4>Four serum miRNAs (miR-133a-3p, miR-584-5p, miR-10b-5p, and miR-221-3p) were significantly overexpressed in LA patients compared with NCs. The diagnostic value of the four-miRNA panel was validated by an external cohort (36 LA vs. 36 NCs). The areas under the receiver operating characteristic curve of the four-miRNA panel in the training, testing, and external validation stages were 0.734, 0.803, and 0.894 respectively. Meanwhile, the expression level of miR-221-3p was much higher in LA tumor samples than that in the adjacent normal tissues (19 LA vs. 19 NCs). The expression level of miR-10b-5p was also elevated in the serum-derived exosomes samples (18 LA vs. 18 NCs). The expression of miR-133a-3p, miR-584-5p, and miR-10b-5p was significantly elevated in LA patients with epidermal growth factor receptor mutation compared with NCs.&lt;h4>Conclusion&lt;/h4>The study established a four-miRNA signature in serum that could improve the diagnostic capability of LA.</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Nov</publication><modification>2024-02-15T19:10:31.743Z</modification><creation>2021-02-20T04:56:17Z</creation></dates><accession>S-EPMC7722592</accession><cross_references><pubmed>32947363</pubmed><doi>10.1097/CM9.0000000000001100</doi></cross_references></HashMap>